【正文】
UB), 20082010Figure 329: Forecast for Parapharmaceutical Market (Billion RUB), 20112013Figure 330: Nutritional Supplements Market (Million US$), 20082010Figure 331: Share of Imported amp。 Domestic Nutritional Supplements (2010)Figure 332: Deaths by Circulatory System Diseases (Million), 2002, 2006 amp。 2010Figure 333: Hepatitis C Market (Million US$), 20092013Figure 334: Number of HIV Patients (Million), 20082010Figure 335: Number of Diagnosed Diabetes Patients (Million), 2010 amp。 2030Figure 336: Insulin Market (Million US$), 20072010Figure 337: Cancer Deaths (Per 100,000), 2002, 2006 amp。 2010Figure 41: Number of Clinical Trials Approved (20072010)Figure 42: Number of Patients Planned to be recruited in Clinical Trials (20082010)Figure 43: Clinical Trials by Therapeutic Area (%), 2009Figure 44: Clinical Trials by Sponsor Country (%), 2009Figure 51: Commercial Drug Sales by Price Category (%), 2008 amp。 2009Figure 52: Personal Disposable Ine (Billion US$), 20092013Figure 53: Forecast for Population (Million), 20112013List of Tables:Table 31: Sales Structure of ATC Groups in Commercial Drugs Market (2009)Table 32: Leading Pharmaceutical Companies in Commercial Drugs Market by Sales (Million RUB), 2009Table 33: Leading Drugs in Commercial Drugs Market by Sales (Million RUB), 2009Table 34: Drugs Sales Structure of ATC Groups under DLO Program (2009)Table 35: Leading Pharmaceutical Companies under DLO Program by Sales (Million RUB), 2009Table 36: Leading Drugs under DLO Program by Sales (Million RUB), 2009Table 37: Sales Structure of ATC Groups in Hospital Segment (2009)Table 38: Leading Pharmaceutical Companies by Sales under Hospital Segment (Million RUB), 2009Table 39: Leading Trade Names under Hospital Segment by Sales (Million RUB), 2009Table 41: Number of Clinical Trials by Top Six Sponsors (2009)Table 71: SanofiAventis Strengths amp。 WeaknessesTable 72: Novartis Pharma ZAO Strengths amp。 WeaknessesTable 73: Roche Moscow Ltd. Strengths amp。 WeaknessesTable 74: Farmstandart OAO Strengths amp。 WeaknessesTable 75: Akrikhin OAO Strengths amp。 Weaknesses窗體